<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

        <ul class="navbar-nav ml-auto">
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
          </ul>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div class="row">
          <div class="col-sm-9 col-7">
            <h1 class="mb-4">Drive-PK Study Design</h1>
          </div>
          <div class="col-sm-3 col-5">
            <span class="badge blue-dark float-right mt-1">Status: Completed</span>
          </div>

          <div class="col-md-12">
            <ul class="mb-4 pl-20">
              <li>Multicenter study (eight sites in North America, six sites in Europe)</li>
              <li>Patients were randomized 1:1 to receive open-label mitapivat 50 mg or 300 mg BID for a 24-week core period</li>
              <li>Eligible patients could opt to continue treatment in an ongoing extension phase</li>
            </ul>
            
            <div class="block">
              <div class="row">
                <div class="col-lg-7 d-flex align-items-center">
                  <img src="images/drive-pk-study-design.png" />
                </div>

                <div class="col-lg-5">
                  <ul class="mb-4 pl-20">
                    <li>Treatment with mitapivat was associated with a rapid, clinically significant increase in hemoglobin in 50% of treated patients
                        <ul class="pl-20">
                          <li>Hemoglobin response was sustained for up to 35 months with ongoing treatment and was associated with improvements in markers of hemolysis</li>
                          <li>Hemoglobin responses were observed in patients with diverse PKLR genotypes, all of whom had a lease one missense mutation</li>
                        </ul>
                       </li>
                       <li>The most common adverse events occurred at drug initiation and were transient
                          <ul class="pl-20">
                            <li>Grade 3 or greater adverse events that were considered by the investigator to be drug related were seen in 17% of patients treated daily for up to 35 months</li>
                          </ul>
                       </li>
                       <li>This study supports the potential of mitapivat as an investigational long-term disease-modifying therapy for PK deficiency</li>
                       <li>The efficacy and safety of mitapivat continue to be studied in the extension phase as well as in two ongoing phase 3 studies (NCT03559699, NCT03548220)</li>
                  </ul>
                </div>
              </div>
            </div>

          </div>
        </div>
        <footer>
            <div class="row">
              <div class="col-md-12">
                <p class="text-left mb-4">‘Drive-PK’ and study schema not included in manuscript.<br/>
                All patients provided written informed consent<br/> 
                aDose adjustments were allowed in the core period on the basis of safety, side-effect profile, and hemoglobin response<br/>
                bProtocol amendments required that patients who did not have an increase from baseline hemoglobin of ≥1.0 g/dL for ≥3 of prior 4 measurements withdraw from the study; and that patients treated with mitapivat doses >25 mg BID undergo a dose taper and continue on a dose that maintained their hemoglobin level at no lower than 1.0 g/dL below their pre-taper hemoglobin level<br/>
                BID = twice daily<br/><br/>
                Grace RF et al. NEJM 2019; 381:933-44.</p>
                <p class="text-right">For more information (physician/HCP only),<br/>
                please email medinfo@agios.com<br/>
                ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
              </div>
            </div>
        </footer>
      </div>
    </main>


    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
  </body>
</html>